Autologous mesenchymal stem cells ( DrugBank: - )


5 diseases
告示番号疾患名(ページ内リンク)臨床試験数
2筋萎縮性側索硬化症9
6パーキンソン病1
13多発性硬化症/視神経脊髄炎12
17多系統萎縮症3
46悪性関節リウマチ1

2. 筋萎縮性側索硬化症


臨床試験数 : 645 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04681118
(ClinicalTrials.gov)
March 24, 202118/12/2020Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALSIntermediate-size Patient Population Expanded Access Protocol: Repeated Administration of Nurown® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisBiological: NurOwn (MSC-NTF cells)Brainstorm-Cell TherapeuticsNULLNo longer available18 Years63 YearsAllUnited States
2NCT03280056
(ClinicalTrials.gov)
August 28, 201729/8/2017Safety and Efficacy of Repeated Administrations of NurOwn® in ALS PatientsA Phase 3, Randomized Double-Blind, Placebo-Controlled Multicenter Study to Evaluate Efficacy and Safety of Repeated Administration of NurOwn® (Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors) in Participants With ALSAmyotrophic Lateral Sclerosis (ALS)Biological: NurOwn® (MSC-NTF cells);Other: Placebo;Other: Bone Marrow aspirationBrainstorm-Cell TherapeuticsCalifornia Institute for Regenerative Medicine (CIRM)Completed18 Years60 YearsAll263Phase 3United States
3NCT04821479
(ClinicalTrials.gov)
January 1, 201619/10/2020Repeated Mesenchymal Stem Cell Injections in ALSSafety and Clinical Effects of Repeated Intrathecal Injections of Autologous Mesenchymal Stem Cells in Patients With Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisBiological: Mesenchymal stem cells (MSC)Hadassah Medical OrganizationNULLCompleted18 Years65 YearsAll20Phase 1/Phase 2NULL
4NCT02987413
(ClinicalTrials.gov)
April 28, 20151/7/2016Escalated Application of Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis PatientsSafety and Efficacy of Mesenchymal Stem Cells Escalated Application in Amyotrophic Lateral Sclerosis Patients: Study Design of a Phase I TrialMotor Neuron DiseaseBiological: Autologous Mesenchymal stem cells (MSCs)Hospital e Maternidade Dr. Christóvão da GamaIEP São Lucas - Instituto de Ensino e Pesquisa;Clinica Jordy Sinapse;TECHLIFE - Centro de Tecnologia CelularCompleted18 YearsN/AAll3Phase 1Brazil
5NCT02017912
(ClinicalTrials.gov)
May 201417/12/2013Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALSA Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate Safety and Efficacy of Transplantation of Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (MSC-NTF) in Patients With ALSAmyotrophic Lateral Sclerosis (ALS)Biological: Autologous MSC-NTF cells;Biological: PlaceboBrainstorm-Cell TherapeuticsNULLCompleted18 Years75 YearsAll48Phase 2United States
6EUCTR2011-006254-85-ES
(EUCTR)
08/02/201309/08/2012Clinical trial to value the safety and efficacy of administration of stem cells derived from own patient for the treatment of Amyotrophic Lateral Sclerosis (ALS).Placebo controlled, randomized and triple blind multicentric phase I/II clinical trial to evaluate the safety, feasibility and valoration of efficacy trends of intravenous administration of three doses of autologous adipose derived autologous mesenchymal stem cells (CeTMAd) in moderate/severe ALS patients. Amyotrophic lateral sclerosis (ALS)
MedDRA version: 14.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Células madre mesenquimales de tejido adiposo autólogo
INN or Proposed INN: NA
Other descriptive name: Células Mesenquimales de tejido adiposo
FUNDACIÓN PROGRESO Y SALUDNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 1/2Spain
7NCT01609283
(ClinicalTrials.gov)
May 201218/5/2012A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral SclerosisA Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral SclerosisAmyotrophic Lateral SclerosisBiological: autologous mesenchymal stem cellsMayo ClinicNULLCompleted18 YearsN/AAll27Phase 1United States
8EUCTR2011-000362-35-CZ
(EUCTR)
29/03/201205/04/2011Safety and Efficacy of Stem Cell Therapy of Motor Neuron Disease.A Prospective, Non-randomized, Open Label Study to Assess the Safety and the Efficacy of Autologous Multipotent Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis. - AMSC in ALS Amyotrophic lateral sclerosis
MedDRA version: 17.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: Suspension of human autologous MSC 3P in 1,5 ml
Product Code: AMSC
INN or Proposed INN: Human autologous mesenchymal stem cells
Bioinova, s.r.o.NULLNot RecruitingFemale: yes
Male: yes
30Phase 2Czech Republic
9NCT01142856
(ClinicalTrials.gov)
June 201010/6/2010Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)A Single Patient Treatment Protocol for Autologous Mesenchymal Stem Cell Intraspinal Therapy in Amyotrophic Lateral Sclerosis (ALS)Amyotrophic Lateral SclerosisBiological: autologous mesenchymal stem cellsMayo ClinicNULLCompleted18 YearsN/ABoth1Phase 1United States

6. パーキンソン病


臨床試験数 : 2,307 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04146519
(ClinicalTrials.gov)
July 1, 201718/10/2019Parkinson's Disease Therapy Using Cell TechnologyDevelopent and Implement a Method of Parkinson's Disease Therapy Using Cell TechnologyTransplantation:Mesenchymal Stem Cell TransplantationBiological: Autologous mesenchymal stem cells;Other: PlaceboBelarusian Medical Academy of Post-Graduate EducationNULLRecruiting18 Years69 YearsAll50Phase 2/Phase 3Belarus

13. 多発性硬化症/視神経脊髄炎


臨床試験数 : 3,340 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03799718
(ClinicalTrials.gov)
March 13, 20197/1/2019Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MSA Phase 2 Open-label Multicenter Study to Evaluate the Safety and Efficacy of Repeated Administration of NurOwn® [Autologous Mesenchymal Stem Cells Secreting Neurotrophic Factors (NTF), MSC-NTF] Cells in Participants With Progressive MSMultiple Sclerosis, Chronic ProgressiveBiological: NurOwn (MSC-NTF cells)Brainstorm-Cell TherapeuticsNULLCompleted18 Years65 YearsAll20Phase 2United States
2NCT02239393
(ClinicalTrials.gov)
June 201510/9/2014Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept StudyMEsenchymal Stem Cell Therapy for CAnadian MS PatientsMultiple SclerosisBiological: Mesenchymal Stem CellsOttawa Hospital Research InstituteNULLCompleted18 Years50 YearsAll31Phase 2Canada
3NCT02495766
(ClinicalTrials.gov)
May 11, 20153/6/2015Autologous Mesenchymal Stromal Cells for Multiple SclerosisTreatment of Autologous Mesenchymal Stem Cells Derived From Bone Marrow as a Potential Therapeutic Strategy for the Treatment of Multiple SclerosisRelapsing-Remitting Multiple Sclerosis;Secondary Progressive Multiple SclerosisDrug: XCEL-MC-ALPHA;Drug: PlaceboBanc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)Completed18 Years60 YearsAll8Phase 1/Phase 2Spain
4EUCTR2012-000734-19-ES
(EUCTR)
10/04/201410/01/2014Bone marrow cell treatment as treatment of multiple sclerosisTreatment of autologous mesenchymal stem cells derived from bone marrow as a potential therapeutic strategy for the treatment of multiple sclerosis - EMMES Multiple Sclerosis
MedDRA version: 16.1;Level: PT;Classification code 10028245;Term: Multiple sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]
Product Name: XCEL-MC-ALPHA
Product Code: XCEL-MC-ALPHA
INN or Proposed INN: Autologous adult mesenchymal stem cells from bone marrow expanded and cryopreserved
Other descriptive name: Mesenchymal Stem Cells
Banc de Sang i TeixitsNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Spain
5NCT02035514
(ClinicalTrials.gov)
December 201317/12/2013Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple SclerosisPhase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple SclerosisRelapsing Remitting Multiple Sclerosis (RRMS)Biological: Bone marrow autologous mesenchymal stem cells transplantationGermans Trias i Pujol HospitalMinisterio de Sanidad, Servicios Sociales e IgualdadCompleted18 Years50 YearsBoth9Phase 1/Phase 2Spain
6NCT01730547
(ClinicalTrials.gov)
February 20139/11/2012Mesenchymal Stem Cells for Multiple SclerosisPhase 1/2 Clinical Trial With Autologous Mesenchymal Stem Cells for the Therapy of Multiple SclerosisMultiple SclerosisBiological: Autologous mesenchymal stem cellsKarolinska InstitutetNULLRecruiting18 Years50 YearsBoth15Phase 1/Phase 2Sweden
7NCT02249676
(ClinicalTrials.gov)
January 201315/9/2014Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum DisordersAutologous Mesenchymal Stem Cells for the Treatment of Progressive and Refractory Neuromyelitis Optica Spectrum Disorders: an Open-label Phase 2a Proof-of-concept StudyDevic's Syndrome;Devic's Neuromyelitis Optica;Devic Syndrome;Devic's Disease;Devic DiseaseBiological: Autologous mesenchymal stem cellsTianjin Medical University General HospitalNULLCompleted18 Years80 YearsAll15Phase 2China
8NCT03778333
(ClinicalTrials.gov)
December 1, 201214/1/2015Mesenchymal Stem Cells for Progressive Multiple Sclerosis_SwedenMesenchymal Stem Cells for Progressive Multiple Sclerosis_SwedenAutologous Mesenchymal Stem Cells;Multiple SclerosisBiological: Autologous mesenchymal stem cellsKarolinska InstitutetNULLCompleted18 Years65 YearsAll7Phase 1Sweden
9NCT01895439
(ClinicalTrials.gov)
October 201224/6/2013Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple SclerosisPhase II Study: Use of Autologus Mesenchymal Stem Cells in Multiple Sclerosis Patients Who do Not Respond to Conventional TreatmentMultiple SclerosisBiological: Autologous Mesenchymal Stem CellsUniversity of JordanNULLCompleted18 Years65 YearsAll13Phase 1/Phase 2Jordan
10NCT01854957
(ClinicalTrials.gov)
July 20128/5/2013MEsenchymal StEm Cells for Multiple SclerosisMEsenchymal StEm Cells for Multiple Sclerosis (MESEMS) Phase I-II Clinical Trial With Autologous Mesenchymal Stem Cells (MSCs) for the Therapy of Multiple SclerosisMultiple SclerosisBiological: Autologous Mesenchymal Stem CellsAntonio UccelliAzienda Ospedaliera Universitaria Integrata Verona;Ospedale San RaffaeleRecruiting18 Years50 YearsBoth20Phase 1/Phase 2Italy
11NCT01228266
(ClinicalTrials.gov)
December 201025/10/2010Mesenchymal Stem Cell Transplantation in MSAutologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: a Randomized, Double-blind, Crossover With Placebo Phase II StudyMultiple SclerosisBiological: autologous mesenchymal stem cellsAlbert SaizInstituto de Salud Carlos IIITerminated18 Years50 YearsBoth9Phase 2Spain
12EUCTR2015-000137-78-AT
(EUCTR)
17/09/2015Mesenchymal stem cells therapy for patients with multiple sclerosisRandomised, double-blind, cross-over phase II study with intravenous autologous mesenchymal stem cells vs. placebo for multiple sclerosis patients in Austria (MESEMS Austria) multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]Product Name: Human autologous mesenchymal stem cells
INN or Proposed INN: MSC2015
Other descriptive name: UNDIFFERENTIATED AUTOLOGOUS MESENCHYMAL STEM CELLS
SALK - Gemeinnützige Salzburger Landeskliniken Betriebsges. m.b.H., Christian-Doppler-Klinik, UK für Neurologie der PMUNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Austria

17. 多系統萎縮症


臨床試験数 : 119 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05167721
(ClinicalTrials.gov)
December 15, 202130/11/2021Randomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System AtrophyRandomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System AtrophyMultiple System AtrophyBiological: Autologous Mesenchymal Stem Cells;Other: PlaceboMayo ClinicNULLRecruiting30 Years70 YearsAll76Phase 2United States
2NCT02315027
(ClinicalTrials.gov)
October 201231/10/2014Mesenchymal Stem Cell Therapy in Multiple System AtrophyIntrathecal Autologous Mesenchymal Stem Cell Therapy in Multiple System Atrophy (MSA) - Effect of Dose and Natural HistoryMSABiological: Autologous Mesenchymal Stem CellsMayo ClinicFood and Drug Administration (FDA);National Institute of Neurological Disorders and Stroke (NINDS)Active, not recruiting30 Years80 YearsAll30Phase 1/Phase 2United States
3NCT00911365
(ClinicalTrials.gov)
May 200826/5/2009Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System AtrophyA Double-blind Placebo-controlled Randomized Clinical Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System AtrophyMultiple System AtrophyBiological: autologous mesenchymal stem cells;Biological: normal salineYonsei UniversityNULLCompletedN/A75 YearsBoth27Phase 2Korea, Republic of

46. 悪性関節リウマチ


臨床試験数 : 4,356 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03333681
(ClinicalTrials.gov)
June 20, 201614/9/2017Evaluation of Stem Cell Therapy Effects on the Immune Response in Rheumatoid Arthritis PatientsEvaluation of Mesenchymal Stem Cell Therapy Effects on the Cellular and Humoral Immune Responses and Additionally Study on the Effect of Chemokines in Homing of the Immune Cells in Refractory Rheumatoid Arthritis PatientsRheumatoid ArthritisBiological: Autologous mesenchymal stem cellsMashhad University of Medical SciencesNULLCompleted35 Years60 YearsFemale15Phase 1NULL